4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/302% above fair value
$12.12−0.88 (-6.74%)
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
4D Molecular Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
4D Molecular Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $260.65M, up 43.9% year over year. For fiscal 2025 it was $195.70M, up 38.5% from the year before. The highest annual figure on record is $195.70M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $195.70M | +38.5% |
| FY2024 | Dec 31, 2024 | $141.30M | +45.5% |
| FY2023 | Dec 31, 2023 | $97.10M | +21.0% |
| FY2022 | Dec 31, 2022 | $80.25M | +30.8% |
| FY2021 | Dec 31, 2021 | $61.36M | +15.7% |
| FY2020 | Dec 31, 2020 | $53.04M | +37.0% |
| FY2019 | Dec 31, 2019 | $38.72M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $69.78M | +41.1% |
| Q2 FY2026 | Jun 30, 2026 | $68.28M | +42.4% |
| Q1 FY2026 | Mar 31, 2026 | $64.98M | +59.7% |
| Q4 FY2025 | Dec 31, 2025 | $57.61M | +33.7% |
| Q3 FY2025 | Sep 30, 2025 | $49.44M | +28.5% |
| Q2 FY2025 | Jun 30, 2025 | $47.95M | +50.5% |
| Q1 FY2025 | Mar 31, 2025 | $40.70M | +46.0% |
| Q4 FY2024 | Dec 31, 2024 | $43.09M | +65.5% |
| Q3 FY2024 | Sep 30, 2024 | $38.48M | +53.5% |
| Q2 FY2024 | Jun 30, 2024 | $31.86M | +35.1% |
| Q1 FY2024 | Mar 31, 2024 | $27.87M | +24.4% |
| Q4 FY2023 | Dec 31, 2023 | $26.03M | +21.1% |
| Q3 FY2023 | Sep 30, 2023 | $25.07M | +32.3% |
| Q2 FY2023 | Jun 30, 2023 | $23.58M | +15.5% |
| Q1 FY2023 | Mar 31, 2023 | $22.41M | +15.6% |
| Q4 FY2022 | Dec 31, 2022 | $21.50M | +22.7% |
| Q3 FY2022 | Sep 30, 2022 | $18.94M | +19.6% |
| Q2 FY2022 | Jun 30, 2022 | $20.42M | +34.2% |
| Q1 FY2022 | Mar 31, 2022 | $19.38M | +51.8% |
| Q4 FY2021 | Dec 31, 2021 | $17.53M | +39.1% |
| Q3 FY2021 | Sep 30, 2021 | $15.84M | +37.1% |
| Q2 FY2021 | Jun 30, 2021 | $15.22M | -3.2% |
| Q1 FY2021 | Mar 31, 2021 | $12.77M | -3.0% |
| Q4 FY2020 | Dec 31, 2020 | $12.61M | – |
| Q3 FY2020 | Sep 30, 2020 | $11.56M | – |
| Q2 FY2020 | Jun 30, 2020 | $15.72M | – |
| Q1 FY2020 | Mar 31, 2020 | $13.16M | – |
See a number that looks wrong?